-Presented initial clinical data for lead allogeneic CAR T program PBCAR0191 for the treatment of NHL and B-ALL-
-Implemented amendment to PBCAR0191 Phase 1/2a trial focused on optimizing clinical activity, CAR T cell expansion and persistence-
-Received FDA IND clearance and Orphan Drug Designation for two additional wholly-owned allogeneic CAR T programs targeting CD20 and BCMA; expect clinical trials to begin in 2020-
-Announced first wholly-owned in vivo gene correction program targeting primary hyperoxaluria type 1 (PH1), a rare genetic disease; expect clinical candidate to be selected in 2020-
-Achieved proof-of-concept for Elo Life Systems’ ZeroMelonTM zero calorie watermelon-based sweetener program; expect to move to greenhouse trials in 2020-
DURHAM, N.C., March 10, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, today announced financial results for the fourth quarter and fiscal year ended December 31, 2019, and provided a business update.
“The considerable progress we made in 2019, our first year as a public company, positions Precision BioSciences to further accelerate development across all areas of our portfolio,” commented Matt Kane, CEO and co-founder of Precision BioSciences. “We now have three clinical-stage allogeneic CAR T candidates in development for the treatment of NHL, B-ALL, CLL/SLL and multiple myeloma, and have the clinical team and resources to focus on rapidly advancing these programs. We look forward to providing meaningful updates on their progress during 2020. Over the past year, we also built and opened our first-in-class cGMP-compliant manufacturing facility, advanced our partnered and wholly-owned in vivo gene-correction programs, and achieved validating milestones at our food-focused subsidiary, Elo Life Systems. I am very proud of the achievements of the entire Precision team in 2019 and am excited to continue this impressive pace of progress in 2020.”
Recent Developments and Upcoming Milestones
Allogeneic CAR T portfolio
Presented initial clinical data for lead CD19-targeted allogeneic CAR T candidate PBCAR0191; dose escalation continuing on-track with further updates expected during 2020. IND applications cleared for wholly-owned CD20 and BCMA targeted CAR T programs. PBCAR20A clinical trial set to begin at higher dose level, accelerating development
- On December 9, 2019, Precision presented initial results from the ongoing Phase 1/2a trial of its lead allogeneic chimeric antigen receptor (CAR) T product candidate, PBCAR0191. Data included adult patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL) treated at the lowest two dose levels (Dose Level 1, 3x105 cells/kg; Dose Level 2, 1x106 cells/kg). No dose-limiting toxicities or cases of graft-versus-host disease were observed. Early evidence of dose dependent, cell-mediated anti-cancer activity was observed. In the NHL cohort, four out of six patients treated across Dose Levels 1 and 2 achieved an objective response at day 28+, for an objective response rate of 67%. Two of three NHL patients treated at Dose Level 1 achieved partial responses at day 28+. Responses at day 28+ were seen to deepen in the three NHL patients treated at Dose Level 2, with one patient achieving a complete response and one patient achieving a partial response. In the B-ALL cohort, one of three patients treated at Dose Level 2 achieved a complete response at day 28+; the remaining two B-ALL patients with progressive disease had high disease burden and poor prognostic indicators on entry into the trial.
- The PBCAR0191 trial is ongoing and dosing is progressing as planned. Based on the data observed at Dose Levels 1 and 2, and after discussion with the U.S Food and Drug Administration (FDA), Precision recently implemented an amendment to the PBCAR0191 trial protocol designed to further optimize clinical activity. The amended trial design is intended to specifically address key clinical questions. These include assessing the impact of higher total doses of cells on clinical activity and/or the impact of modified lymphodepletion on the ability to achieve durable clinical benefit with associated CAR T cell expansion and persistence.
- The most important modification is the inclusion of two additional dose levels: Dose Level 4 (6x106 cells/kg) and Dose Level 5 (9x106 cells/kg). These higher doses will employ a split dosing strategy following a single lymphodepletion, with the intention of optimizing clinical activity, while preserving a favorable safety profile. Dose Level 4 will comprise two infusions of 3x106 cells/kg, and Dose Level 5 will comprise three such infusions.
- In addition, Precision now has the option to increase or decrease the doses of fludarabine and cyclophosphamide used in the lymphodepletion protocol if data suggest that CAR T cell rejection limits efficacy.
- The final modification allows for the option to re-dose patients following evidence of clinical response but with subsequent disease progression.
- Precision expects to announce additional clinical data from the PBCAR0191 trial for both the NHL and B-ALL cohorts during 2020. PBCAR0191 is being developed in collaboration with Servier, an international pharmaceutical company.
- In September 2019, the FDA cleared the Investigational New Drug (IND) application for PBCAR20A, Precision’s second and wholly-owned CAR T therapy candidate, which is expected to enter the clinic in Q1 2020. Based on the safety profile so far observed for PBCAR0191, the FDA has permitted Precision to begin dosing with PBCAR20A at Dose Level 2 (1x106 cells/kg), which is expected to accelerate the trial. PBCAR20A is an allogeneic anti-CD20 CAR T therapy candidate in development for the treatment of (1) NHL and (2) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). PBCAR20A has received Orphan Drug Designation from the FDA for the treatment of mantle cell lymphoma.
- In January 2020, the FDA also cleared Precision’s IND application for its third CAR T therapy candidate, PBCAR269A, which is also wholly-owned by Precision and which targets BCMA for the treatment of patients with multiple myeloma. PBCAR269A has received Orphan Drug Designation from the FDA, and dosing of patients in a Phase 1/2a clinical trial is expected to begin in 2020.
In vivo gene correction portfolio
Lead in vivo gene correction program identified, clinical candidate selection expected in 2020
- In January 2020, Precision announced that it expects to advance its first wholly-owned in vivo gene correction program for the treatment of primary hyperoxaluria type 1 (PH1), a rare genetic disease. In collaboration with Dr. Jim Wilson’s group at the University of Pennsylvania, Precision has generated encouraging preclinical data demonstrating that one-time administration of an ARCUS nuclease can efficiently knock out the validated target gene HAO1 in hepatocytes of non-human primates, and can reduce urine oxalate, a known PH1 biomarker, by up to 70% in a mouse model. In 2020, Precision expects to select a clinical candidate for this program to advance into human trials.
- In partnership with Gilead, Precision is developing an in vivo gene correction program to potentially cure chronic infection with the hepatitis B virus. Submission of an IND for this product candidate is currently targeted for 2021.
Elo Life Systems
Advanced Elo Life Systems’ key food and agriculture programs
- Elo’s partnered program with Cargill focuses on developing canola oil with ultra-low saturated fatty acids. In 2019, the partnership was able to demonstrate progress towards the goal of achieving a product with